Abstract #535
Time: 8:00AM - 12:00PM
Location: Level 2, West Hall D1, W240A
Outcome prediction by the 70-gene profile in the context of the National
Comprehensive Cancer Network (NCCN) guideline
F. A. de Snoo, M. Knauer, R. A. Bender, L. Stork-Sloots, E. J. Rutgers,
A. M. Glas, S. C. Linn, L. J. Van 't Veer
Date: Sunday, May 31, 2009
POSTER PRESENTATION
Abstract #4036
Time: 8:00 AM - 12:00 PM
Location: Level 2, West Hall C
Development and validation of a robust prognostic and predictive
signature for colorectal cancer (CRC) patients
A. M. Glas, P. Roepman, R. Salazar, G. Capella, V. Moreno, J. Westerga,
P. J. Kuppen, I. Simon, L. J. Van 't Veer, R. Tollenaar
Date: Sunday, May 31, 2009
POSTER DISCUSSION
Abstract #518
Time: 8:00AM - 12:00PM
Location: Level 2, West Hall D1, W240A
Early determination of metastatic potential in breast cancer: the 70-gene
signature in small tumors
M. Knauer, S. Mook, V. Retel, M. Kok, J. Wesseling, A. M. Glas, E. J.
Rutgers, L. J. van 't Veer, S. C. Linn
Date: Monday, June 01, 2009
POSTER PRESENTATION
Abstract #11083
Time: 1:00PM - 5:00PM
Location: Level 2, West Hall C
Combining multi-gene profiling of molecular subtypes with the 70-gene
profile for classification of breast cancer
L. Stork-Sloots, O. Krijgsman, P. Roepman, F. A. de Snoo, R. A. Bender,
A. M. Glas
About MammaPrint(R)
MammaPrint is the first 'in vitro diagnostic multivariate index assay'
(IVDMIA) cleared by the U.S. Food and Drug Administration (FDA). FDA
clearance requires clinical and analytical validation and reporting systems
to ensure patient safety issues are addressed. Highly accurate, MammaPrint
identifies patients with early metastasis-patients who are likely to develop
metastases within five years following surgery. Several authoritative studies
have shown t
'/>"/>
SOURCE Agendia B.V. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
Agendia BV Appoints Mr. Hessel Lindenbergh as Chairman of its Supervisory Board2.
Agendia Joins the Personalized Medicine Coalition (PMC)3.
Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test4.
Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award5.
Agendia BV Appoints Clinical and Scientific Advisory Board6.
Agendia and Agilent Announce Plans to Jointly Develop New Diagnostic Tests, Extend Supply Agreement7.
Agendias MammaPrint(R) Receives Prestigious Award From Dutch Innovation Platform8.
Agendia and Ferrer Announce Exclusive Agreement for Sales of Cancer Diagnostic Services in Four Major European Markets9.
Agendia Appoints New Chief Financial Officer10.
Agendias Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL11.
Agendia Appoints VP of Business Development